PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: Results of a randomized phase IIa trial

Australasian Journal of Dermatology

Volumn 51, Issue 2, 2010, Pages 99-105

  Siller, Greg ^a,b   Rosen, Robert ^c   Freeman, Michael ^d   Welburn, Peter ^e   Katsamas, Janelle ^e   Ogbourne, Steven M ^e  

^a Siller Medical   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Skin Centre   (Australia)

^d Peplin Ltd   (Australia)

^e Southern Suburbs Dermatology   (Australia)

Author keywords

Anti neoplastic agent; Ingenol mebutate; Ingenol 3 angelate; Non melanoma skin cancer; PEP005

Indexed keywords

INGENOL; PEP005; UNCLASSIFIED DRUG;

ADULT; AGED; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ARTICLE; AUSTRALIA; BASAL CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EROSION; ERYTHEMA; FEMALE; GEL; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; HYPOPIGMENTATION; INCIDENCE; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRURITUS; PUNCH BIOPSY; PUSTULE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN CRUSTING; SKIN DISEASE; SKIN EDEMA; SKIN EXUDATE; SKIN FLACKING; SKIN MANIFESTATION; SKIN SCABBING; SKIN SCALING; SKIN ULCER; SKIN VESICLE; SKIN WEEPING; SORE THROAT; TELANGIECTASIA; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GELS; HEADACHE; HUMANS; MALE; MIDDLE AGED; PAIN; REMISSION INDUCTION; SKIN DISEASES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77951989505     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2010.00626.x     Document Type: Article

References (15)

1. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N. Engl. J. Med. 1992 327 : 1649 1662.
2. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003 327 : 794 798.
3. Holme SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br. J. Dermatol. 2000 143 : 1224 1229. (Pubitemid 32052759)
4. de Vries E, van de Poll-Franse LV, Louwman WJ et al. Predictions of skin cancer incidence in the Netherlands up to 2015. Br. J. Dermatol. 2005 152 : 481 488. (Pubitemid 40547122)
5. Australian Institute of Health and Welfare (AIHW), Cancer Australia. Non-melanoma skin cancer: general practice consultations, hospitalisation and mortality. Cancer series no. 43. Cat. no. 39. Canberra: AIHW, 2008.
6. Lee S, Selva D, Huilgol SC et al. Pharmacological treatments for basal cell carcinoma. Drugs 2007 67 : 915 934. (Pubitemid 46607391)
7. Maiden JH. Weeds of New South Wales. Ag. Gazette NSW 1917 28 : 131 132.
8. Weedon D, Chick J. Home treatment of basal cell carcinoma. Med. J. Aust. 1976 1 : 928.
9. Green AC, Beardmore GL. Home treatment of skin cancer and solar keratoses. Australas. J. Dermatol. 1988 29 : 127 130.
10. Ogbourne SM, Suhrbier A, Jones B et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004 64 : 2833 2839. (Pubitemid 38500622)
11. Challacombe JM, Suhrbier A, Parsons PG et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J. Immunol. 2006 177 : 8123 8132. (Pubitemid 44846331)
12. Hampson P, Kavanagh D, Smith E et al. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner. Cancer Immunol. Immunother. 2008 57 : 1241 1251.
13. Telfer NR, Colver GB, Morton CA et al. Guidelines for the management of basal cell carcinoma. Br. J. Dermatol. 2008 159 : 35 48. (Pubitemid 351874512)
14. Siller G, Gebauer K, Welburn P et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas. J. Dermatol. 2009 50 : 16 22.
15. Anderson LL, Schmieder GJ, Werschler WP et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J. Am. Acad. Dermatol. 2009 60 : 934 943.